Cargando…
BCR-ABL1 is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia
Several cases such as myeloproliferative neoplasms (MPN) with the coexistence of JAK2 and BCR-ABL have been reported. However, cases of transformation of essential thrombocythemia (ET) into chronic myeloid leukemia (CML) during the disease progression were rarely reported. Here, we report the case o...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742103/ https://www.ncbi.nlm.nih.gov/pubmed/36518237 http://dx.doi.org/10.1097/BS9.0000000000000129 |
_version_ | 1784848461573652480 |
---|---|
author | Zhang, Yanqing Bi, Hailiang Wang, Ying Chen, Long Pan, Jiaqi Xu, Ping Wang, Wei Yang, Shaobin |
author_facet | Zhang, Yanqing Bi, Hailiang Wang, Ying Chen, Long Pan, Jiaqi Xu, Ping Wang, Wei Yang, Shaobin |
author_sort | Zhang, Yanqing |
collection | PubMed |
description | Several cases such as myeloproliferative neoplasms (MPN) with the coexistence of JAK2 and BCR-ABL have been reported. However, cases of transformation of essential thrombocythemia (ET) into chronic myeloid leukemia (CML) during the disease progression were rarely reported. Here, we report the case of a patient with JAK2 V617F- positive ET who subsequently acquired BCR–ABL1, which transformed the disease into CML after 10 years from the initial diagnosis. In this study, we dynamically monitored JAK2 V617F and BCR-ABL and observed multiple gene mutations, including IDH2, IDH1, ASXL1, KRAS, and RUNX1. It is important to be aware of this potentially clone evolution in disease progression. |
format | Online Article Text |
id | pubmed-9742103 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-97421032022-12-13 BCR-ABL1 is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia Zhang, Yanqing Bi, Hailiang Wang, Ying Chen, Long Pan, Jiaqi Xu, Ping Wang, Wei Yang, Shaobin Blood Sci Case Report Several cases such as myeloproliferative neoplasms (MPN) with the coexistence of JAK2 and BCR-ABL have been reported. However, cases of transformation of essential thrombocythemia (ET) into chronic myeloid leukemia (CML) during the disease progression were rarely reported. Here, we report the case of a patient with JAK2 V617F- positive ET who subsequently acquired BCR–ABL1, which transformed the disease into CML after 10 years from the initial diagnosis. In this study, we dynamically monitored JAK2 V617F and BCR-ABL and observed multiple gene mutations, including IDH2, IDH1, ASXL1, KRAS, and RUNX1. It is important to be aware of this potentially clone evolution in disease progression. Lippincott Williams & Wilkins 2022-08-01 /pmc/articles/PMC9742103/ /pubmed/36518237 http://dx.doi.org/10.1097/BS9.0000000000000129 Text en Copyright © 2022 The Authors. Published by Wolters Kluwer Health Inc., on behalf of the Chinese Medical Association (CMA) and Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College (IHCAMS). https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Zhang, Yanqing Bi, Hailiang Wang, Ying Chen, Long Pan, Jiaqi Xu, Ping Wang, Wei Yang, Shaobin BCR-ABL1 is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia |
title | BCR-ABL1 is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia |
title_full | BCR-ABL1 is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia |
title_fullStr | BCR-ABL1 is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia |
title_full_unstemmed | BCR-ABL1 is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia |
title_short | BCR-ABL1 is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia |
title_sort | bcr-abl1 is a secondary event after jak2v617f in a patient with essential thrombocythemia who develop chronic myeloid leukemia |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742103/ https://www.ncbi.nlm.nih.gov/pubmed/36518237 http://dx.doi.org/10.1097/BS9.0000000000000129 |
work_keys_str_mv | AT zhangyanqing bcrabl1isasecondaryeventafterjak2v617finapatientwithessentialthrombocythemiawhodevelopchronicmyeloidleukemia AT bihailiang bcrabl1isasecondaryeventafterjak2v617finapatientwithessentialthrombocythemiawhodevelopchronicmyeloidleukemia AT wangying bcrabl1isasecondaryeventafterjak2v617finapatientwithessentialthrombocythemiawhodevelopchronicmyeloidleukemia AT chenlong bcrabl1isasecondaryeventafterjak2v617finapatientwithessentialthrombocythemiawhodevelopchronicmyeloidleukemia AT panjiaqi bcrabl1isasecondaryeventafterjak2v617finapatientwithessentialthrombocythemiawhodevelopchronicmyeloidleukemia AT xuping bcrabl1isasecondaryeventafterjak2v617finapatientwithessentialthrombocythemiawhodevelopchronicmyeloidleukemia AT wangwei bcrabl1isasecondaryeventafterjak2v617finapatientwithessentialthrombocythemiawhodevelopchronicmyeloidleukemia AT yangshaobin bcrabl1isasecondaryeventafterjak2v617finapatientwithessentialthrombocythemiawhodevelopchronicmyeloidleukemia |